TSE:GUD Knight Therapeutics (GUD) Stock Price, News & Analysis → 4x Better than Bitcoin (From Behind the Markets) (Ad) Free GUD Stock Alerts C$5.30 -0.14 (-2.57%) (As of 03/28/2024 ET) Add Compare Share Share Today's RangeC$5.29▼C$5.4850-Day RangeC$5.23▼C$5.7252-Week RangeC$4.30▼C$5.75Volume35,785 shsAverage Volume78,192 shsMarket CapitalizationC$536.20 millionP/E RatioN/ADividend YieldN/APrice TargetC$6.58 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Knight Therapeutics alerts: Email Address Knight Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside24.2% UpsideC$6.58 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 12 Articles This WeekInsider TradingAcquiring SharesC$1.84 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.55 out of 5 stars 2.5 Analyst's Opinion Consensus RatingKnight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$6.58, Knight Therapeutics has a forecasted upside of 24.2% from its current price of C$5.30.Amount of Analyst CoverageKnight Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GUD. Previous Next 0.0 Dividend Strength Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GUD. Previous Next 2.9 News and Social Media Coverage News SentimentKnight Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Knight Therapeutics this week, compared to 0 articles on an average week.Search Interest2 people have searched for GUD on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Knight Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have bought 168.86% more of their company's stock than they have sold. Specifically, they have bought C$1,842,750.00 in company stock and sold C$685,400.00 in company stock.Percentage Held by Insiders46.45% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.75% of the stock of Knight Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Knight Therapeutics is -33.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Knight Therapeutics is -33.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.Price to Book Value per Share RatioKnight Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Knight Therapeutics Stock (TSE:GUD)Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.Read More GUD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GUD Stock News HeadlinesMarch 26, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Acquires 351,000 SharesMarch 25, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Knight Therapeutics Inc. Reduced by Analyst (TSE:GUD)March 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 23, 2024 | investing.comEarnings call: Knight Therapeutics announced record revenues of $343 millionMarch 23, 2024 | americanbankingnews.comKnight Therapeutics (TSE:GUD) Given New C$7.00 Price Target at Royal Bank of CanadaMarch 22, 2024 | finance.yahoo.comKnight Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 20, 2024 | ca.finance.yahoo.comKnight Therapeutics Inc (04K.SG)March 19, 2024 | americanbankingnews.comKnight Therapeutics (GUD) Set to Announce Earnings on ThursdayMarch 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 14, 2024 | ca.finance.yahoo.comStocks in play: Knight Therapeutics Inc.March 7, 2024 | finance.yahoo.comFavourable Signals For Knight Therapeutics: Numerous Insiders Acquired StockFebruary 29, 2024 | ca.finance.yahoo.comStocks in play: Knight Therapeutics Inc.,February 29, 2024 | msn.comKnight Therapeutics launches Minjuvi in BrazilFebruary 21, 2024 | finance.yahoo.comKnight Therapeutics Announces Regulatory Submission of Fostamatinib in BrazilJanuary 4, 2024 | finance.yahoo.comKnight Therapeutics Announces Product Launch for IMVEXXY® in CanadaDecember 19, 2023 | finance.yahoo.comKnight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in CanadaOctober 2, 2023 | finance.yahoo.comKnight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing CompaniesSeptember 14, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc flat on Thursday (GUD)August 12, 2023 | markets.businessinsider.comKnight Therapeutics (KHTRF) Receives a Buy from RBC CapitalAugust 10, 2023 | theglobeandmail.comTrading For This Specialty Pharma Company is up Following Second Quarter ResultsAugust 10, 2023 | finance.yahoo.comKnight Therapeutics Reports Second Quarter 2023 ResultsAugust 3, 2023 | finance.yahoo.comNotice of Knight Therapeutics' Second Quarter 2023 Results Conference CallJune 7, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc up on Tuesday (GUD)June 2, 2023 | finance.yahoo.comKnight to Present at the Jefferies 2023 Healthcare Conference in New York CityMay 31, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc down on Wednesday (GUD)May 26, 2023 | finance.yahoo.comSamira Sakhia Bought 12% More Shares In Knight TherapeuticsMay 26, 2023 | finance.yahoo.comSamira Sakhia Bought 12% More Shares In Knight Therapeutics \See More Headlines Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Next Earnings (Estimated)5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:GUD CUSIPN/A CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees725Year FoundedN/APrice Target and Rating Average Stock Price TargetC$6.58 High Stock Price TargetC$7.50 Low Stock Price TargetC$5.25 Potential Upside/Downside+24.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.16) Trailing P/E RatioN/A Forward P/E Ratio262.17 P/E Growth-1013.5Net IncomeC$-16,840,000.00 Net Margins-5.13% Pretax MarginN/A Return on Equity-2.14% Return on Assets0.40% Debt Debt-to-Equity Ratio9.25 Current Ratio3.20 Quick Ratio1.79 Sales & Book Value Annual SalesC$328.20 million Price / Sales1.63 Cash FlowC$1.38 per share Price / Cash Flow3.85 Book ValueC$7.38 per share Price / Book0.72Miscellaneous Outstanding Shares101,170,000Free FloatN/AMarket CapC$536.20 million OptionableNot Optionable Beta0.49 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Jonathan Ross Goodman B.A. (Age 55)L.L.B., M.B.A., Executive Chairman Comp: $250.94kMs. Samira Sakhia BCom (Age 56)CA, CPA, MBA, President, CEO & Director Comp: $674.28kMr. Arvind UtchanahChief Financial OfficerMs. Amal Khouri B.Sc.M.B.A., Chief Business OfficerMr. Jeff MartensGlobal Vice President of CommercialMr. Stephani SaverioVice President of Business DevelopmentMr. Leopoldo BosanoVice-President of Manufacturing & OperationsMs. Monica PercarioGlobal Vice President of Scientific AffairsMr. Henrique DiasGlobal Director of MarketingMs. Susan Caroline EmblemGlobal Vice President of Human ResourcesMore ExecutivesKey CompetitorsOrganigramTSE:OGIAurora CannabisTSE:ACBSupreme CannabisTSE:FIREESSA PharmaCVE:EPICipher PharmaceuticalsTSE:CPHView All CompetitorsInsidersSime ArmoyanBought 351,000 shares on 3/25/2024Total: C$1.84 M ($5.25/share)Sime ArmoyanSold 28,200 sharesTotal: C$162,150.00 ($5.75/share)Sime ArmoyanSold 91,000 sharesTotal: C$523,250.00 ($5.75/share)Sime ArmoyanBought 1,100 shares on 10/23/2023Total: C$4,785.00 ($4.35/share)Sime ArmoyanBought 26,400 shares on 9/15/2023Total: C$115,737.60 ($4.38/share)View All Insider Transactions GUD Stock Analysis - Frequently Asked Questions Should I buy or sell Knight Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GUD shares. View GUD analyst ratings or view top-rated stocks. What is Knight Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued 1-year target prices for Knight Therapeutics' shares. Their GUD share price targets range from C$5.25 to C$7.50. On average, they anticipate the company's share price to reach C$6.58 in the next twelve months. This suggests a possible upside of 24.2% from the stock's current price. View analysts price targets for GUD or view top-rated stocks among Wall Street analysts. How have GUD shares performed in 2024? Knight Therapeutics' stock was trading at C$5.19 at the beginning of the year. Since then, GUD stock has increased by 2.1% and is now trading at C$5.30. View the best growth stocks for 2024 here. When is Knight Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GUD earnings forecast. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B), Chemtrade Logistics Income Fund (CHE.UN), Canadian National Railway (CNR), Dollarama (DOL) and Extendicare (EXE). How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:GUD) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss Ratings“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.